Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-01

Clinical Trial Update: Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria [Phase 2]

View source ↗

Summary

Phase 2 study of TMX-049 in type 2 diabetes with albuminuria has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TMX-049

Snippet

Sponsor: Teijin America, Inc. | Conditions: Diabetic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-08-01